ClinicalTrials.gg
Enrolling by invitationNCT03618186Updated Jun 12, 2026

Neuroimaging Study

A Phase 2 interventional study of Tau PET scan in Cognitive Impairment, sponsored by Mayo Clinic. Enrolling by invitation at 2 sites in United States. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Cognitive Dysfunction by Mayo Clinic — 7 open to participants now, 9 under way, none of them phase 3. Cognitive Dysfunction · Mayo Clinic.

Planned enrollment
3rd of 17
240 · median 42
Started
2018
with 2 others
Phase 2
5 of 22
2 open now
Registered
8th of 22
by date

Among the 22 studies in Cognitive Dysfunction by Mayo Clinic, this one is the 3rd largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2018, is one of 5 in phase 2, and was the 8th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

7 of the 22 studies in Cognitive Dysfunction by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 30 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Cognitive Dysfunction by Mayo Clinic, or all of them as a file.
02

Study summary

The researchers are trying to gather information and learn more about imaging tests in racially different people who are cognitively normal or have dementia.

03

Conditions studied

  • Cognitive Impairment

Keywords

  • African Americans
  • neurological exam
  • Dementia
  • Alzheimer's Disease
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female African Americans 30 years of age or older
  • Subjects who have completed or are scheduled to undergo the neurological evaluation procedures described below.

Exclusion criteria

Exclusion Criteria:

  • Subjects unable to lie down without moving for 20 minutes.
  • Women who are pregnant or cannot stop breast feeding for 24 hours.
  • Claustrophobic patients unable to tolerate the scans.
  • Subjects with a prolonged (as demonstrated by test) cannot participate in the Tau-PET scans.
  • Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc, since the quantitative PET data analysis is based on anatomic criteria that are established uniquely for each subject by registration to his/her MRI.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Normal control

    Cognitively normal volunteers

    Combination Product: Tau PET scan

  • Experimental
    Mild Cogntive impairment

    Person with cognitive impairment that meet Peterson Criteria

    Combination Product: Tau PET scan

  • Experimental
    Demented

    Patient's that meet dementia criteria

    Combination Product: Tau PET scan

Interventions

  • Combination productTau PET scan

    Patient will receive a dose of flutaucipir and be scanned appropriately

06

What researchers measure

Primary outcomes

  1. Tau positive scans

    Percentage of each of the three groups with tau positive scans

    Time frame: 5 years

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2018 (actual). Primary completion is estimated for May 2030, 138 months after the start.

Of 145 non-industry phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 64. This study's planned 138 months is above that.

Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2018
First posted
Aug 7, 2018
StartActual
Nov 26, 2018
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03618186
Lead sponsor
Mayo Clinic
Responsible party
Neill R. Graff-Radford, M.D. (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Aug 7, 2018
Start date
Nov 26, 2018
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Jun 12, 2026

Study contacts

Neill R Graff-Radford, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion